1. An evaluation and risk assessment of a patient conducted pursuant to paragraph (b) of subsection 1 of NRS 639.23911 must include, without limitation:
(a) Obtaining and reviewing a relevant medical history of the patient.
(b) Conducting a physical examination of the patient directed to the source of the patient’s pain and within the scope of practice of the practitioner.
(c) If the prescription is for a quantity of a controlled substance listed in schedule II, III or IV that is intended to be used in not less than 30 days:
(1) Making a good faith effort to obtain and review any medical records of the patient from any other provider of health care who has provided care to the patient that are relevant to the prescription; and
(2) Documenting efforts to obtain such medical records and the conclusions from reviewing any such medical records in the medical record of the patient.
(d) Assessing the mental health and risk of abuse, dependency and addiction of the patient using methods supported by peer-reviewed scientific research and validated by a nationally recognized organization.
2. The informed consent obtained pursuant to paragraph (e) of subsection 1 of NRS 639.23911 must include, where applicable, information concerning:
(a) The potential risks and benefits of treatment using the controlled substance, including if a form of the controlled substance that is designed to deter abuse is available, the risks and benefits of using that form;
(b) Proper use of the controlled substance;
(c) Any alternative means of treating the symptoms of the patient and the cause of such symptoms;
(d) The important provisions of the treatment plan established for the patient pursuant to paragraph (c) of subsection 1 of NRS 639.23911 in a clear and simple manner;
(e) The risks of dependency, addiction and overdose during treatment using the controlled substance;
(f) Methods to safely store and legally dispose of the controlled substance;
(g) The manner in which the practitioner will address requests for refills of the prescription, including, without limitation, an explanation of the provisions of NRS 639.23913, if applicable;
(h) If the patient is a woman between 15 and 45 years of age, the risk to a fetus of chronic exposure to controlled substances during pregnancy, including, without limitation, the risks of fetal dependency on the controlled substance and neonatal abstinence syndrome;
(i) If the controlled substance is an opioid, the availability of an opioid antagonist, as defined in NRS 453C.040, without a prescription; and
(j) If the patient is an unemancipated minor, the risks that the minor will abuse or misuse the controlled substance or divert the controlled substance for use by another person and ways to detect such abuse, misuse or diversion.
3. A practitioner shall document a conversation in which a patient provided informed consent that meets the requirements of subsection 2 in the medical record of the patient. If a patient provides informed written consent, the practitioner must include the document on which the informed consent is recorded in the medical record of the patient.
(Added to NRS by 2017, 4431; A 2019, 2138)